Breast Biopsy Market Size was valued at USD 0.58 Billion in 2022. The Breast Biopsy Market industry is projected to grow from USD 0.64 Billion in 2023 to USD 1.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). The increasing technological upgrades in the field of breast biopsy and molecular imaging are market drivers expediting the market’s expansion.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Although breast biopsies may also be performed to rule out other conditions discovered during a physical examination, they are most usually used to detect breast cancer. The Breast Biopsy industry may be segmented using a variety of techniques. Fine needle aspiration biopsy, which produces no scars and is widely performed for breast biopsies, is one of the least invasive therapies. Breast cancer can be caused by various lifestyle factors, including drinking alcohol, becoming overweight, utilizing birth control, receiving hormone therapy for menopause, and getting breast implants. The reason that is projected to encourage the rise of the breast biopsy instruments market is a boost in life expectancy. A needle is introduced into the dermal tissue on the breast to remove tissue.
The alternate method, stereotactic needle biopsy, guides the biopsy with mammography and ultrasound radiation. The ultrasound machine serves as a guide for the needle when it is inserted into the breast during this procedure. Stereotactic mammography employs pictures taken from multiple angles to locate the breast tumor and determine where to insert the needle to take a breast biopsy sample. The severity of breast cancer may worsen due to changes in a person's way of life, including behavior, dietary preferences, and physical activity. Increased blood insulin levels are found in overweight women. High insulin levels have been associated with certain malignancies, including breast cancer. In addition, a sophisticated biopsy approach would make it possible for radiologists and doctors to execute breast surgeries.
Breast biopsy technology, which assists in treating many cancer patients, makes early cancer detection possible. Many cancer-related deaths are attributed to inaccurate cancer tissue identification. Breast biopsy equipment that relies on imaging has completely transformed the bioimaging industry and significantly boosted the use of molecular pictures. With new technology, players are given excellent opportunities to enter and dominate this market. The rising incidence of breast cancer will soon drive the need for breast biopsy instruments. Due to a combination of factors, including a growing population, a changing lifestyle, and excessive alcohol and tobacco use, there is an increase in the worldwide burden of breast cancer. Breast cancer is a significant public health concern in low- and middle-income nations.
In January 2023, Hologic Inc. received FDA approval for a new breast biopsy system: A leading company in the market for breast biopsy, Hologic Inc., has announced that it has been granted U.S. Food and Drug Administration approval for its Affirm Prone Biopsy system, which is innovative. To improve patients’ ease and enhance diagnosis precision, the system minimizes invasive breast biopsies.
For example, in March 2022, today Hologic, Inc. launched its Innovation Center in Aix-en-Provence, France; this is an innovative healthcare technology company focused primarily on improving women’s health. The ultrasound commercial office (R&D), training center and commercial offices are part of Hologic’s broader continuum of care solutions in interventional radiology for women with breast problems.
In March 2022, C.R. Bard Inc. Announced the Acquisition by BD: Becton, Dickinson and Company (BD) has fully acquired C.R. Bard, which is a well-known company involved in the production of breast biopsy tools and equipment. BD will be significantly bolstered by this acquisition as they take up various CR Bard devices used in taking tissue specimens for examination or surgery cases with the hope to give room for more treatment options while driving innovation and further growing markets.
In August 2021, Ethicon Endo-Surgery Collaborates with Research Institutions for Breast Biopsy Research: Collaboration between Ethicon Endo-Surgery and prestigious research institutions aims at advancing the development of minimal invasiveness within core biopsies for the breasts. This strategic partnership exemplifies Ethicon's commitment to innovation within the field of mammography by aiming to improve accuracy rates as well as efficiency levels attained when performing core biopsies, especially through these procedures.
In April 2021, Unilabs formed an alliance with GE Healthcare. In Portugal, GE Healthcare supplies Unilabs with technically advanced MRIs & CT scanning technology, ultrasound devices, mammography and x-ray machines.
IZI Medical Products, LLC ("IZI") introduced the Quick-Core Auto Biopsy System ("Quick-Core Auto") for soft tissue biopsy in March’2021. Quick-Core Auto is a wholly automatic biopsy apparatus and lightweight equipment, as it provides accuracy, reliability, and quality similar to that of IZI’s semi-automatic Quick-Core systems.
Market CAGR for breast biopsy is being driven by the rise in technological upgrades in the breast biopsy market as well as the increasing spread of breast cancer among the population of the world. The market’s growth is significantly influenced by the rising incidence of breast cancer. The World Health Organization (WHO) lists breast cancer as one of the leading causes of mortality. In 2020, breast cancer affected the lives of 685,000 individuals worldwide, affecting 2.3 million women. Breast cancer, which had been discovered in 7.8 million women over the preceding five years, was the most prevalent in the world as of the year 2020. Early cancer detection is made possible by breast biopsy technology, which aids in the treatment of many cancer patients. Lack of accuracy in identifying cancerous tissues is blamed for the majority of cancer-related deaths. The bio-imaging sector has been fully converted by imaging-based breast biopsy instruments, which have considerably increased the usage of molecular images.
Growing developments in molecular imaging-related technologies are a key element fueling the market's expansion in terms of revenue. For instance, The NearWave Imager, a novel imaging device for identifying and monitoring breast cancer, achieved prototype stage on March 15, 2022, at the University of Notre Dame. One of the prime reasons propelling the market's expansion is the growth of research & development activities for the development of platforms of breast biopsy to treat chronic breast diseases. The growth of technologies has been possible by the increasing research & development initiatives taken by various institutions across world. Such technologies' effectiveness makes it easier for them to enter the market.
Additionally, the development of technologically improved, minimally invasive breast biopsy instruments, increased breast biopsy awareness, and an increase in the number of elderly women all contribute to the market's rapid expansion. The market is expected to grow at a healthy rate due to rising government funding initiatives for breast cancer research, rising awareness of early detection of the disease, the trend towards minimally invasive surgery, and the availability of pathologists and radiologists in both developed and developing nations. Thus, driving the Breast Biopsy Market revenue.
The Breast Biopsy Market segmentation, based on product includes Biopsy needles and Biopsy tables. The section that accounts for a large portion is biopsy needles. This expansion is consistent with its broad application in the market for needle breast biopsies. The products sector appears to have experienced the majority of improvements and breakthroughs. For instance, the Stryker PreciseCore needle makes it possible to acquire samples more precisely and with significantly lower risks of causing tissue injury. Furthermore, a significant growth rate is projected for the guiding systems product segment during the course of the forecast year.
The Breast Biopsy Market segmentation, based on technique type, includes Fine needle aspiration biopsy, and Core needle biopsy. The market for fine needle aspiration biopsy is anticipated to have the greatest share, mostly as a result of an increase in demand for minimally invasive procedures. In contrast, the core needle biopsy is predicted to expand at a high CAGR value over the course of the forecast period because it is a less invasive procedure that includes creating a small incision through which the needle is inserted and then obtaining a sample using a vacuum-powered device.
The Breast Biopsy Market segmentation, based on guidance technology, includes Ultrasound-guided, and CT-guided. The process guided by ultrasound produces more precise results and is projected to see the highest growth rate throughout the course of the study. Hence, the ultrasound-guided category is anticipated to grow fastest.
The Breast Biopsy Market segmentation, based on end-user, includes Hospitals, and Labs. The largest share belonged to the hospitals segment. Hospitals were the largest category since there were more breast cancer screenings there. The availability of highly skilled staff in these facilities who are technical experts in the treatment and diagnosis of breast cancer was another factor that helped the market grow.
Figure 1: Breast Biopsy Market, by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
News:
A recent study suggests that a clinical decision support tool based on deep learning can help decrease needless breast biopsies. Houston Methodist Hospital researchers created the intelligent-augmented breast cancer risk calculator, or iBRISK, to assess women's risk of contracting the illness. The technique was developed by researchers using clinical risk factors and mammographic descriptors from 9,700 patients who had images taken at their institution. It was then validated on an additional 1,000+ patients. Researchers recently evaluated iBRISK on a new, independent dataset of breast pictures from 4,209 more individuals scanned at three Texas institutions between 2006 and 2016. The model was created primarily to evaluate the likelihood of cancer in lesions classified as category 4 by the Breast Imaging Reporting and Data System (BI-RADS).
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Breast Biopsy Market area will dominate this market. Because of the increase in awareness brought about by cancer screening programmes and other supportive government measures, North America makes up the majority of the sector.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BREAST BIOPSY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe’s Breast Biopsy Market accounts for the second-largest position in the market. The market is expanding at an accelerated rate due to the trend towards image-guided needle biopsies and less invasive biopsies. Further, the German Breast Biopsy Market held the largest market share, and the UK Breast Biopsy Market was the quickest-growing market in the European region
The Asia Pacific Breast Biopsy Market is anticipated to expand at the quickest CAGR. The region's fast-growing economies have made investments in the construction of healthcare infrastructure, which is fueling market expansion. Moreover, China Breast Biopsy Market held the fastest CAGR, and the India Breast Biopsy Market was the quickest-growing market in the Asia-Pacific region.
Breast Biopsy Key Market Players & Competitive Insights
Leading market players are investing largely in research and development to grow their product/service lines, which will aid the Breast Biopsy Market, to grow even faster. Market leaders are also adopting a variety of strategies to expand their worldwide position, with important market developments including new product launches & developments, contractual agreements among companies with complementary service lines, mergers & acquisitions, higher investments, & collaboration with other organizations having complementary products and services. To grow in a competitive and rising market climate, the Breast Biopsy industry needs to offer cost-efficient products.
Producing locally to cut operational expenses is one of the prime business strategies used by manufacturers in the Breast Biopsy industry to benefit clients and increase the market sector. In recent years, the Breast Biopsy industry has served with some of the key perks to medicine. Major players in the Breast Biopsy Market, including Medical Technologies LLC, STERYLAB S.r.l., ARGON MEDICAL, Danaher, Cianna Medical, United Medical Systems Inc., Stryker, Hologic Inc., Devicor Medical Products Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, and others are attempting to increase market growth via investing in research and development operations.
A maker of specialized medical devices with a presence, Argon Medical is based in Plano, Texas. For interventional radiology, interventional cardiology, and oncology, Argon provides a wide range of medical instruments. Best-in-class solutions under the Argon brand are known for enhancing patient outcomes through percutaneous, image-guided procedures. Argon services its customers through a direct sales organization, as well as through enduring connections with medical device distributors, key partners, and OEMs, by using a well-established sales and marketing infrastructure. In May 2023, The SuperCore Advantage Semi-Automatic Biopsy Instrument has been introduced in the United States by Argon Medical Devices, a leading supplier of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology.
Stryker Corp (Stryker), a pioneer in medical technology, is a manufacturer of a range of orthopaedic, medical, surgical, neurotechnology, and spine apparatus as well as associated services. Orthopaedic implants, surgical equipment & navigation systems, disposable intensive care items, and endoscopic & communication systems are among the company's primary products. Additionally, it provides spinal devices, neurosurgical equipment, and medical equipment for use in a variety of illnesses. Stryker sells items to physicians, hospitals, and other medical facilities. The corporation supplies its products through subsidiaries, branches, independent dealers, and distributors across globe. The US city of Kalamazoo, Michigan, is home to Stryker's headquarters. The company provides its products & services through various subsidiaries, distributors, third-party dealers, and suppliers across the all the regions. Stryker is headquartered in Kalamazoo, Michigan, the US. In September 2022, The U.S. Food and Drug Administration granted the OptaBlate bone tumour ablation system (OptaBlate) 510(k) approval, according to a statement from Stryker. With the involvement of OptaBlate, Stryker's Interventional Spine (IVS) portfolio is now offering a full range of therapeutic options for metastatic vertebral body fractures, building on its existing core capabilities in vertebral augmentation and radiofrequency ablation.
Key Companies in the Breast Biopsy Market include
Medical Technologies LLC
STERYLAB S.r.l.
ARGON MEDICAL
Danaher
Cianna Medical
Hologic Inc.
Devicor Medical Products Inc.
F. Hoffmann-La Roche Ltd.
OncoCyte Corporation
Breast Biopsy Industry Developments
July 2021:Serena Bright will be installed by GE Healthcare at five hospitals and radiology facilities across the country. The first contrast-guided biopsy product in the market, Serena Bright, supports patients and clinicians in their battle against breast cancer.
January 2023:The Atlas of Breast Cancer Early Detection, a new digital atlas, has been released, as per International Agency for Research on Cancer (IARC). The atlas provides step-by-step instructions for performing image-guided fine-needle aspiration cytology, diagnostic mammography, diagnostic breast ultrasound, image-guided fine-needle aspiration cytology, and core breast biopsy.
Biopsy needles
Biopsy tables
Fine needle aspiration biopsy
Core needle biopsy
Ultrasound-guided
CT-guided
Hospitals
Labs
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.58 Billion |
| Market Size 2023 | USD 0.64 Billion |
| Market Size 2032 | USD 1.38 Billion |
| Compound Annual Growth Rate (CAGR) | 10.10% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technique Type, Guidance Technology, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Medical Technologies LLC, STERYLAB S.r.l., ARGON MEDICAL, Danaher, Cianna Medical, United Medical Systems Inc., Stryker, Hologic Inc., Devicor Medical Products Inc., F. Hoffmann-La Roche Ltd. |
| Key Market Opportunities | Growing technological updates |
| Key Market Dynamics | Increasing prevalence of breast cancer |
Frequently Asked Questions (FAQ) :
The Breast Biopsy Market size was valued at USD 0.58 Billion in 2022.
The market is projected to grow at a CAGR of 10.10% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in the market are Medical Technologies LLC, STERYLAB S.r.l., ARGON MEDICAL, Danaher, Cianna Medical, United Medical Systems Inc., Stryker, Hologic Inc., Devicor Medical Products Inc., F. Hoffmann-La Roche Ltd.
The biopsy needles category dominated the market in 2022.
The hospital had the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
